Materias dentro de su búsqueda.
Mostrando 841 - 860 Resultados de 15,180 Para Buscar '"Hepatitis C"', tiempo de consulta: 0.36s Limitar resultados
  1. 841
    “…BACKGROUND: Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C
  2. 842
    por Chen, Chi‐Yi, Huang, Chung‐Feng, Cheng, Pin‐Nan, Tseng, Kuo‐Chih, Lo, Ching‐Chu, Kuo, Hsing‐Tao, Huang, Yi‐Hsiang, Tai, Chi‐Ming, Peng, Cheng‐Yuan, Bair, Ming‐Jong, Chen, Chien‐Hung, Yeh, Ming‐Lun, Lin, Chih‐Lang, Lin, Chun‐Yen, Lee, Pei‐Lun, Chong, Lee‐Won, Hung, Chao‐Hung, Huang, Jee‐Fu, Yang, Chi‐Chieh, Hu, Jui‐Ting, Lin, Chih‐Wen, Chen, Chun‐Ting, Wang, Chia‐Chi, Su, Wei‐Wen, Hsieh, Tsai‐Yuan, Lin, Chih‐Lin, Tsai, Wei‐Lun, Lee, Tzong‐Hsi, Chen, Guei‐Ying, Wang, Szu‐Jen, Chang, Chun‐Chao, Mo, Lein‐Ray, Yang, Sheng‐Shun, Wu, Wen‐Chih, Huang, Chia‐Sheng, Hsiung, Chou‐Kwok, Kao, Chien‐Neng, Tsai, Pei‐Chien, Liu, Chen‐Hua, Lee, Mei‐Hsuan, Liu, Chun‐Jen, Dai, Chia‐Yen, Kao, Jia‐Horng, Chuang, Wan‐Long, Lin, Han‐Chieh, Yu, Ming‐Lung
    Publicado 2021
    “…BACKGROUND/AIMS: Direct‐acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)‐infected patients. The real‐world treatment outcome in Taiwanese patients on a nationwide basis is elusive. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
  3. 843
    “…In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study
  4. 844
    “…RESULTS: Liver fibrosis did not change in 88.9% of patients in Group hepatitis C virus Rx and in 77.4% in Group hepatitis C virus untreated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients
  5. 845
    “…Certain hepatitis C virus (HCV) carriers exhibit persistently normal alanine aminotransferase (ALT) levels (PNALT) (≤30 IU/l) accompanied by normal platelet counts (≥15×10(4)/μl); these individuals show milder disease activity and slower progression to cirrhosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C
  6. 846
    “…Resolution of chronic hepatitis C is considered when serum HCV RNA becomes repeatedly undetectable and liver enzymes normalize. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Persistence of Hepatitis C Virus during and after Otherwise Clinically Successful Treatment of Chronic Hepatitis C with Standard Pegylated Interferon α-2b and Ribavirin Therapy
  7. 847
    “…OBJECTIVE: To establish the role of liver fibrosis as a predictive tool of response to pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) treatment in human immunodeficiency (HIV)/hepatitis C virus (HCV) coinfected patients, in addition to recognized predictive factors (HCV load, HCV genotype, IL-28B polymorphism). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients
  8. 848
    “…Chronic hepatitis C is a serious liver disease that often results in cirrhosis or hepatocellular carcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Genetic Variants in Human Leukocyte Antigen-DP Influence Both Hepatitis C Virus Persistence and Hepatitis C Virus F Protein Generation in the Chinese Han Population
  9. 849
    “…The impact of sex on metabolic alterations in individuals with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection remains elusive. A community-based study was performed to assess sex, age, body mass index, the lipid profile, blood pressure, glucose, alanine aminotransferase, HBV surface antigen (HBsAg), and HCV antibody levels, smoking and alcohol drinking habits, and cardiometabolic diseases, including diabetes, hypertension, cardiovascular events, and renal diseases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area
  10. 850
    “…We assessed non‐liver‐related non–acquired immunodeficiency syndrome (AIDS)‐related (NLR‐NAR) events and mortality in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)–coinfected patients treated with interferon (IFN) and ribavirin (RBV), between 2000 and 2008. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection
  11. 851
    “…BACKGROUND: Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% of patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial
  12. 852
    “…The results of the study demonstrate that DMEs protein abundances in the liver are affected by hepatitis C virus infection and depend on the severity of the disease.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers
  13. 853
    “…Globally, there are approximately 58 million people with chronic hepatitis C virus infection (HCV) but only 20% have been diagnosed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-effectiveness of Hepatitis C virus self-testing in four settings
  14. 854
    “…INTRODUCTION: Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV vaccine development. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Convergent antibody responses are associated with broad neutralization of hepatitis C virus
  15. 855
    “…The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
  16. 856
    “…The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment. Short courses of treatment with these drugs are highly beneficial to patients, eliminating hepatitis C virus (HCV) without adverse effects. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies
  17. 857
    por Origa, Raffaella
    Publicado 2023
    “…Donor screening has nearly eliminated the risk of hepatitis C virus post-transfusion transmission in resource-rich settings. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending
  18. 858
    “…BACKGROUND: Successful treatment of hepatitis C reduces liver inflammation and fibrosis; however, patients remain at risk of developing hepatocellular carcinoma (HCC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis
  19. 859
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dual versus triple therapy in treatment of hepatitis C virus (HCV)
  20. 860
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hepatitis C Virus Clearance Cascade — United States, 2013–2022
Herramientas de búsqueda: RSS